Project Grant R43AI192169
Award Date 8/15/25
Completion Date 7/31/27
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- This federal Project Grant award of $300,001 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Fimbrion Therapeutics Inc. to develop novel small molecule drugs targeting the respiratory protein QcrB in mycobacteria. The goal is to create new antimicrobial therapies to treat infections caused by non-tuberculous mycobacteria (NTM), which are highly resistant to existing antibiotics...
- This Project Grant award of $427,625.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to exploit bacteriophages (viruses that infect bacteria) to discover novel anti-biofilm agents. The goal is to improve phage therapy and identify proteins that could be developed as stand-alone therapeutics to treat biofilm-associated infections, which are a particular concern for the opportunistic pathogen Pseudomonas aeruginosa....
- This Project Grant, valued at $868,776.00 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports research to characterize a novel post-transcriptional regulator in the opportunistic pathogen Pseudomonas aeruginosa. The key objectives are to identify the direct regulatory targets of this regulator, called PhAF, under standard laboratory conditions and in clinically relevant...
- This $407,156 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of chemical probes to explore the utility of recruiting the complement system for eliminating antibiotic-resistant bacterial pathogens. The research aims to generate multifunctional compounds that bind to the bacterium Pseudomonas aeruginosa and assess their ability to promote pathogen uptake...
- This $392,634 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The project aims to design, fabricate, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant killing while...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000 in funding to Fimbrion Therapeutics Inc. in Missouri to develop an orally bioavailable thiazolino-pyridone (TZP) small molecule series with inhibitory activity against Mycobacterium tuberculosis. The goal is to create a first-in-class TZP compound that could become a novel drug for treating...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vast Therapeutics, Inc. a $2,000,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel nitric oxide-releasing formulation (ALX1) for the treatment of Pseudomonas aeruginosa infections in bronchiectasis patients. The objective is to answer critical questions needed to initiate Phase II proof-of-concept clinical trials for this broad-spectrum antibacterial therapy,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $779,915 Project Grant to the Scripps Research Institute to investigate the chromatin remodeling functions of polyphosphate condensates in the bacterial pathogen Pseudomonas aeruginosa. The grant, awarded under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), will support research to understand how polyphosphate, a polymer produced by bacteria in response to stress, interacts with the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $105,076 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Dartmouth College to study the dual function of the T6SS immunity protein TSIT in regulating Pseudomonas aeruginosa biofilm growth. The research aims to test the hypothesis that TSIT acts as a transcription factor, in addition to its role as a T6SS immunity protein, to regulate biofilm formation - a key...
- This Project Grant award, valued at $160,040.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research conducted by the University of California, San Francisco (UCSF) to investigate how the bacterial pathogen Pseudomonas aeruginosa senses and responds to mechanical deformation of its cell envelope when contacting surfaces. The research aims to further...